amifostine anhydrous has been researched along with Bone Marrow Diseases in 8 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Bone Marrow Diseases: Diseases involving the BONE MARROW.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of mitomycin for metastatic colorectal cancer has been limited by mitomycin's myelosuppressive potential." | 9.07 | Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. ( Baker, L; Gullo, JJ; Leming, PD; Lokich, JJ; LoRusso, P; McCulloch, W; Poplin, EA; Schein, P; Schulz, JJ; Veach, SR, 1994) |
| "The use of mitomycin for metastatic colorectal cancer has been limited by mitomycin's myelosuppressive potential." | 5.07 | Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. ( Baker, L; Gullo, JJ; Leming, PD; Lokich, JJ; LoRusso, P; McCulloch, W; Poplin, EA; Schein, P; Schulz, JJ; Veach, SR, 1994) |
| " These results with a small number of patients suggest that amifostine given with carboplatin may reduce the duration of thrombocytopenia and hospitalisation." | 2.68 | Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. ( Anderson, H; Betticher, DC; Meely, K; Oster, W; Ranson, M; Thatcher, N, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, W | 1 |
| Chen, Q | 1 |
| Wu, S | 1 |
| Xia, X | 1 |
| Wu, A | 1 |
| Cui, F | 1 |
| Gu, YP | 1 |
| Zhang, X | 1 |
| Cao, J | 1 |
| Treskes, M | 1 |
| van der Vijgh, WJ | 1 |
| Green, D | 1 |
| Bensely, D | 1 |
| Schein, P | 2 |
| Poplin, EA | 1 |
| LoRusso, P | 1 |
| Lokich, JJ | 1 |
| Gullo, JJ | 1 |
| Leming, PD | 1 |
| Schulz, JJ | 1 |
| Veach, SR | 1 |
| McCulloch, W | 1 |
| Baker, L | 1 |
| Betticher, DC | 1 |
| Anderson, H | 1 |
| Ranson, M | 1 |
| Meely, K | 1 |
| Oster, W | 1 |
| Thatcher, N | 1 |
| Alberts, DS | 1 |
| Selvaggi, G | 1 |
| Belani, CP | 1 |
| Fulda, S | 1 |
| Fichtner, I | 1 |
| Hero, B | 1 |
| Berthold, F | 1 |
3 reviews available for amifostine anhydrous and Bone Marrow Diseases
| Article | Year |
|---|---|
WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
Topics: Amifostine; Animals; Bone Marrow Diseases; Carboplatin; Cisplatin; Ear Diseases; Gastrointestinal Di | 1993 |
Protection by amifostine of cyclophosphamide-induced myelosuppression.
Topics: Amifostine; Antineoplastic Agents, Alkylating; Bone Marrow Diseases; Clinical Trials as Topic; Cyclo | 1999 |
Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carci | 1999 |
3 trials available for amifostine anhydrous and Bone Marrow Diseases
| Article | Year |
|---|---|
Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer.
Topics: Adult; Aged; Amifostine; Bone Marrow Diseases; Colorectal Neoplasms; Female; Humans; Male; Middle Ag | 1994 |
Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Carcinoma, Non-Sm | 1995 |
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Topics: Adolescent; Amifostine; Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Cell Divi | 2001 |
2 other studies available for amifostine anhydrous and Bone Marrow Diseases
| Article | Year |
|---|---|
Radioprotector WR-2721 and mitigating peptidoglycan synergistically promote mouse survival through the amelioration of intestinal and bone marrow damage.
Topics: Amifostine; Animals; Bone Marrow Diseases; Drug Synergism; Intestinal Diseases; Male; Mice; Mice, In | 2015 |
Preclinical evaluation of WR-151327: an orally active chemotherapy protector.
Topics: Administration, Oral; Amifostine; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Bo | 1994 |